

CURRICULUM VITAE

Name: Robert K. Stuart, M.D.

Office: Hematology/Oncology Division (843) 792-4271
Medical University of South Carolina
96 Jonathan Lucas Street - 903 CSB
P.O. Box 250623
Charleston, SC 29425

EDUCATION:

Georgetown University, Washington, D.C.
B.S. *magna cum laude*, Psychology
1966 - 1970

The Johns Hopkins University School of Medicine, Baltimore, Maryland
M.D.
1970 - 1974

The Johns Hopkins Hospital, Baltimore, Maryland
Intern in Medicine
1974 - 1975

The Johns Hopkins Hospital, Baltimore, Maryland
Assistant Resident in Medicine
1975 - 1976

The Johns Hopkins Hospital School of Medicine, Baltimore, Maryland
Fellow in Oncology and Medicine
1976 - 1978

The Johns Hopkins Hospital, Baltimore, Maryland
Associate Staff, Oncology
1976 - 1979

Sloan-Kettering Institute, New York, New York
Research Fellow, Section of Developmental Hematopoiesis
1978 - 1979

FACULTY APPOINTMENTS:

Assistant Professor of Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland
1979 - 1984

Associate Professor of Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland
1984 - 1985

Professor of Medicine
Medical University of South Carolina
Charleston, South Carolina
1985 – 1997

Adjunct Professor of Medicine
Medical University of South Carolina
Charleston, South Carolina
1997 – 2001

Professor of Medicine
Medical University of South Carolina
Charleston, South Carolina
2001 –

HOSPITAL APPOINTMENTS:

Active Staff, Oncology and Medicine
The Johns Hopkins Hospital
Baltimore, Maryland
1978 - 1985

Active Staff
Medical University of South Carolina
Charleston, South Carolina
1985 - 1997

Active Staff
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia
1997 - 2001

Active Staff
Medical University of South Carolina
Charleston, South Carolina
2001 –

ADMINISTRATIVE APPOINTMENTS:

Director, Division of Hematology/Oncology, Department of Medicine
Medical University of South Carolina
Charleston, South Carolina
1985-1996

Associate Director for Clinical Trials, Ernest F. Hollings Cancer Center
Medical University of South Carolina
Charleston, South Carolina
1993 - 1997

Chairman, Department of Oncology
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia
1997 – 2001

Medical Director, Clinical Trials Office, Ernest F. Hollings Cancer Center
Medical University of South Carolina
Charleston, South Carolina
2007 -

SPECIALTY CERTIFICATION:

1977 Diplomate, American Board of Internal Medicine
1979 Diplomate, American Board of Internal Medicine (Medical Oncology)
1986 Diplomate, American Board of Internal Medicine (Hematology)

LICENSURE:

1975 - 1985 Licensed to Practice Medicine, State of Maryland
1985 - South Carolina State Licensure

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

1980 - International Society for Experimental Hematology
1981 - American Society of Hematology
1982 - American Society of Clinical Oncology
1985 - American Federation of Clinical Research
1986 - American Association for Cancer Research
1992 - Charleston County Medical Society
1995 - Society for Biological Therapy
1996 - Southern Medical Association

BOARD MEMBERSHIPS:

Aplastic Anemia Foundation of America, Inc.

1983 - 1990 Secretary

1990 - 1993 Vice President

1993 - 1997 Medical Advisory Board

Hospice of Charleston, Inc.

1985 - 1993 Board of Directors

1993 - 1997 Medical Advisory Board

Charleston Ballet Theatre

1991 - 1997 Board of Directors

Cancer and Leukemia Group B

1995 - 1997 Board of Directors

COOPERATIVE RESEARCH GROUP MEMBERSHIP:

1979 - 1985 Eastern Cooperative Oncology Group/Member
Johns Hopkins Oncology Center

1986 - 1997 Piedmont Oncology Association
Principal Investigator
Medical University of South Carolina

1986 - 1995 Cancer and Leukemia Group B
Affiliate of Bowman Gray School of Medicine
Principal Investigator
Medical University of South Carolina

1993 - 1997 National Surgical Adjuvant Breast and Bowel Project
Principal Investigator (1993 - 1995)
Medical University of South Carolina

- 1995 - 1997 Cancer and Leukemia Group B Main Member
Principal Investigator
Medical University of South Carolina
- 1995 - 1997 Radiation Therapy Oncology Group (RTOG)
Member
Medical University of South Carolina
- 2003 - Southwest Oncology Group (SWOG)
Principal Investigator
Medical University of South Carolina
- 2003 - Southwest Oncology Group (SWOG)
Member
Leukemia and Lymphoma Committees

COMMITTEE MEMBERSHIP:

- 1981 - 1984 Subcommittee on Leukocyte Physiology
American Society of Hematology
(Chairman, 1983)
- 1981 - 1985 Nutrition Advisory Committee
Johns Hopkins Hospital Medical Board
(Chairman, 1982-1984)
- 1982 - 1984 Medical Care Evaluation Committee
Johns Hopkins Hospital Medical Board
- 1982 - 1985 Graduate Committee (for D. Szeluga Ph. D.)
The Graduate School, Cornell University
Ithaca, New York (Thesis Advisor)
- 1986 – 1989 Transfusion Practice Committee
Medical University of South Carolina
Medical Center
- 1986 - 1989 Graduate Committee (for R. Peters, M.D., Ph.D.)
Colleges of Medicine and Graduate Studies
Medical University of South Carolina (Thesis Advisor)
- 1987 - 1997 Institutional Review Board for Human Research
Medical University of South Carolina

- 1987 - 1992 Steering Committee Ernest F. Hollings Oncology Center
Medical University of South Carolina
- 1989 - 1990 Fiscal and Functional Subcommittee (Chairman)
Ernest F. Hollings Oncology Center
Medical University of South Carolina
- 1992 - 1995 Graduate Committee (for J.C. Schultz, Ph.D.)
College of Graduate Studies
Medical University of South Carolina
- 1992 - 1997 Executive Committee, Ernest F. Hollings Cancer Center
Medical University of South Carolina
- 1992 - 1997 Cancer Committee, Naval Hospital,
Beaufort, South Carolina
- 1993 - 1994 Graduate Committee (Vidya Ponnathpur, M.S.)
College of Graduate Studies
Medical University of South Carolina
- 1994 - 1996 Graduate Committee (for Gloria Bullock, M.D., Ph.D.)
Colleges of Medicine and Graduate Studies
Medical University of South Carolina
- 1995 - 1997 Association of Hematology and Oncology Program Directors
- 2003 Graduate Committee (for Marion B. Gillespie, M.D., M.S.)
Colleges of Medicine and Graduate Studies
Medical University of South Carolina
- 2006 - Data Monitoring Committee, H. Lee Moffitt Cancer Center

HONORS:

- 1969 Phi Beta Kappa
- 1970 Magna cum Laude, Georgetown University
- 1973 Henry Strong Denison Scholar
- 1974 Alpha Omega Alpha
- 1974 Mosby Scholarship Award
- 1979 - 1980 Junior Faculty Clinical Fellow, American Cancer Society, Inc.

1980 – 1982 Special Fellow, Leukemia Society of America, Inc.

1996 – 2000 Elected by his peers for inclusion in Best Doctors in America®

2000 - Who's Who in America

2004 Champions of Advocacy Award, American Society of Hematology

2004 Partners in Progress Award, Leukemia and Lymphoma Society

2007 - Who's Who Among American Teachers & Educators

2007 Physician Healthcare Hero, Charleston Regional Business Journal

2007-2008 Elected by his peers for inclusion in Best Doctors in America®

ARTICLES PUBLISHED IN PROFESSIONAL JOURNALS:

1. **Stuart, R. K.**, Salyer, W. R., Salyer, D. C. and Heptinstall, R. H. Renomedullary Interstitial Cell Lesions and Hypertension. *Human Pathol.* 7: 327, 1976.
2. **Stuart, R. K.** and Sensenbrenner, L. L. Adverse Effects of Nutritional Deprivation on Transplanted Hematopoietic Cells. *Exp. Hematol.* 7: 435, 1979.
3. **Stuart, R. K.**, Braine, H. G., Saral, R., Lietman, P. and Fuller, D. Carbenicillin-Trimethoprim/Sulfamethoxazole Versus Carbenicillin-Gentamicin as Empiric Therapy of Infection in Granulocytopenic Patients: A Prospective, Randomized, Double-Blind Study. *Am. J. Med.* 68: 876, 1980.
4. Sharkis, S. J., Spivak, J. L., Ahmed, A., Misiti, J., **Stuart, R. K.**, Wiktor-Jedrzejczak, W., Sell, K. W. and Sensenbrenner, L. L. Regulation of Hematopoiesis: Helper and suppressor Influences of the Thymus. *Blood* 55: 524, 1980.
5. **Stuart, R. K.** and Hamilton, J. A. Tumor Promoting Phorbol Esters Stimulate Hematopoietic Colony Formation In Vitro. *Science* 208: 402, 1980.
6. Spivak, J. L., Misiti, J., **Stuart, R. K.**, Sharkis, S. J. and Sensenbrenner, L. L. Suppression and Potentiation of Mouse Hematopoietic Progenitor Cell Proliferation by Oubain. *Blood* 56: 315, 1980.
7. **Stuart, R. K.** Preleukemia. In Clinical Conferences at The Johns Hopkins Hospital (Simons, E. R. and Cohen, J. L., Eds.). *Johns Hopkins Med. J.* 148: 200-204, 1981.
8. **Stuart, R. K.**, Hamilton, J. A., Sensenbrenner, L. L. and Moore, M. A. S. Regulation of Myelopoiesis In Vitro: Partial Replacement of Colony-Stimulating Factors by Tumor-Promoting Phorbol Esters. *Blood* 57: 1032, 1981.
9. Sieber, F., **Stuart, R. K.** and Spivak, J. L. Tumor-Promoting Phorbol Esters Stimulate Myelopoiesis and Suppress Erythropoiesis in Cultures of Mouse Bone Marrow Cells. *Proc. Natl. Acad. Sci., U.S.A.* 78: 4402-4406, 1981.
10. Wingard, J. R., **Stuart, R. K.**, Saral, R. and Burns, W. H. Activity of Trifluorothymidine Against Cytomegalovirus. *Antimicrob. Agents Chemother.* 20: 286-290, 1981.
11. Delaney, W. E., Nickloff, E., Ettinger, D. S., Drew, H. M., Szeluga, D. J. and **Stuart, R. K.** Abnormal Fatty Acid Breath Tests in Cancer Patients with Nutritional Correlation. *Cancer* 50: 727-731, 1982.
12. Delaney, W. E., **Stuart, R. K.** and Ettinger, D. S. Fatty Acid Breath Test Values in the Malabsorption Range in Cancer Patients. *Nutrition and Cancer* 3: 122-128, 1982.

13. Braine, H. G., **Stuart, R. K.**, Saral, R. and Lietman P. S. Parenteral Trimethoprim-Sulfamethoxazole and Carbenicillin as Empiric Therapy for Neutropenic Patients with Cancer. *Reviews of Infectious Diseases* 4: 586-592, 1982.
14. **Stuart, R. K.** and Pollack, M. Pseudomonas Aeruginosa Exotoxin A Inhibits Proliferation of Human Bone Marrow Progenitor Cells In Vitro. *Infection and Immunity* 38: 206-211, 1982.
15. Strauss, L. C., **Stuart, R. K.** and Civin, C. I. Antigenic Analysis of Hematopoiesis: I. Expression of the MY-1 Granulocyte Surface Antigen on Human Marrow Cell and Leukemic Cell Lines. *Blood* 61: 1222-1231, 1982.
16. Wingard, J. R., Hess, A. D., **Stuart, R. K.**, Saral, R. and Burns, W. H. Effect of Several Antivirals on Human Lymphocyte Functions and Marrow Progenitor Cell Proliferation. *Antimicrob. Agents Chemother.*, 23: 593-597, 1983.
17. Camitta, B., O'Reilly, R. J., Sensenbrenner, L. L., Rapoport, J., Champlin, R., Doney, K., August, C., Hoffman, R. G., Kirkpatrick, D., **Stuart, R. K.**, Santos, G., Parkman, R., Gale, R. P., Storb, R. and Nathan, D. Antithoracic Duct Lymphocyte Globulin Therapy of Severe Aplastic Anemia. *Blood* 62: 883-888, 1983.
18. **Stuart, R. K.**, Sensenbrenner, L. L., Shadduck, R. K., Waheed, A. and Caramatti, C. Phorbol Ester Stimulated Murine Myelopoiesis: Role of Colony Stimulating Factors. *J. Cell Physiol.* 117: 30-38, 1983.
19. Santos, G. W., Tutschka, P. J., Brookmeyer, R., Saral, R., Beschorner, W. E., Bias, W. B., Braine, H. G., Burns, W. H., Wlfenbein, G. J., Kaizer, H., Mellits, D., Sensenbrenner, L. L., **Stuart, R. K.** and Yeager, A. M. Marrow Transplantation for Acute Non-Lymphocytic Leukemia following Treatment with Busulfan and Cyclophosphamide. *N. Eng. J. Med.*, 309: 1347-1353, 1983.
20. Kaizer, H., Tutschka, P., **Stuart, R. K.**, Korbling, M., Braine, H. G., Saral, R., Colvin, M. and Santos, G. Autologous Bone Marrow Transplantation in Acute Leukemia and Non-Hodgkin's Lymphoma: A Phase I Study of 4-Hydroperoxycyclophosphamide (4HC) Incubation of Marrow Prior to Cryopreservation. In: Hematology and Blood Transfusion. *Modern in Human Leukemia V.* Springer-Verlag, Berlin Heidelberg, 28: 116-123, 1983.
21. Szeluga, D. J., **Stuart, R. K.**, Utermohlen, V. and Santos, G. W. Nutritional Assessment by Isotope Dilution of Body Composition. *American Journal of Clinical Nutrition*, 40: 847-854, 1984.
22. Szeluga, D. J., **Stuart, R. K.**, Brookmeyer, R., Utermohlen, V. and Santos, G. W. Energy Requirements of Parenterally-Fed Bone Marrow Transplant Recipients. *Journal of Parenteral and Enteral Nutrition*, 9: 139-143, 1985.

23. Dick, J. D., Rosengard, B. R., Merz, W. G., **Stuart, R. K.**, Hutchins, G. M. and Saral, R. Fatal Disseminated Candidiasis Due to Amphotericin B Resistant Candida guilliermondii. Ann. Int. Med., 102: 67-68, 1985.
24. Rowley, S. D., Colvin, O. M. and **Stuart, R. K.** Human Multi-lineage Progenitor Cell (CFU-GEMM) Sensitivity to 4-Hydroperoxycyclophosphamide. Exp. Hematol., 13: 295-298, 1985.
25. Kaizer, H., **Stuart, R. K.**, Brookmeyer, R., Beschorner, W. E., Braine, H. G., Burns, W. H., Fuller, D. J., Korbling, M., Mangan, K. F., Saral, R., Sensenbrenner, L. L., Shadduck, R. K., Shende, A. C., Tutschka, P. J., Yeager, A. M., Zinkham, W. H., Colvin, O. M. and Santos, G. W. Autologous Bone Marrow Transplantation (BMT) in Acute Leukemia: A Phase I Study of In Vitro Treatment of Marrow with 4-Hydroperoxycyclophosphamide (4HC) to Purge Tumor Cells. Blood, 65: 1504-1510, 1985.
26. **Stuart, R. K.** and Mangan, K. F. Hematologic and Cytogenetic Remission of 5q-Refractory Anemia after Syngeneic Marrow Transplantation. Am. J. Med., 80: 503-507, 1986.
27. Strauss, L. C., Rowley, S. D., LaRussa, V. F., Sharkis, S. J., **Stuart, R. K.** and Civin, C. I. Antigenic Analysis of Hematopoiesis V: Characterization of My-10 Antigen Expression by Normal Lymphohematopoietic Progenitor Cells. Exper. Hematol. 14:878-886, 1986.
28. Yeager, A. M., Kaizer, H., Santos, G. W., Saral, R., Colvin, O. M., **Stuart, R. K.**, Braine, H. G., Burke, P. J., Ambinder, R. F., Burns, W. H., Fuller, A. A., Davis, J. M., Karp, J. E., May, W. S., Rowley, S. D., Sensenbrenner, L. L., Vogelsang, G. B. and Wingard, J. R. Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide. New England Journal of Medicine, 315: 141-147, 1986.
29. Szeluga, D. J., **Stuart, R. K.**, Brookmeyer, R. Utermohlen, V. and Santos, G. W. Nutritional Support of Bone Marrow Transplant Recipients: A Progressive, Randomized Clinical Trial Comparing Total Parenteral Nutrition to an Enteral Feeding Program. Cancer Research 47, 3309-3316, 1987.
30. Sieber, R., **Stuart, R.**, Rowley, S., Sharkis, S., and Sensenbrenner, L. Dye-Mediated Photolysis of Normal and Neoplastic Hematopoietic Cells. Leukemia Research 11:43-49, 1987.
31. Santos, G., Tutschka, P., Brookmeyer, R., Saral, R., Beschorner, W., Bias, W., Braine, H., Burns, W., Farmer, E., Hess, A., Kaizer, H., Mellits, D., Sensenbrenner, L., **Stuart, R.**, Yeager, A. Cyclosporine plus Methylprednisolone versus Cyclophosphamide plus Methylprednisolone as Prophylaxis for Graft-Versus Host

- Disease: A Randomized Double Blind Study in Patients Undergoing Allogeneic Marrow Transplantation. *Clin Transplantation* 1:21-28, 1987.
32. Braine, H.G., Santos, G.W., Kaizer, H., Yeager, A.M., Mann, R.B., Burns, W.H., Civin, C.I., Fuller, D.J., Rowley, S.D., Saral, R., Sensenbrenner, L.L., **Stuart, R.K.**, Wingard, J.R., Munoz, L.L. Treatment of Poor Prognosis non-Hodgkin's Lymphoma using Cyclophosphamide and Total Body Irradiation Regimens with Autologous Bone Marrow Rescue. *Bone Marrow Transplantation* 2:7-14, 1987.
 33. Garvin, A. Julian, M.D. Ph.D., Self, Sally, M.D., Sahovic, Entezam A., M.D., **Stuart, Robert K.**, Marchalonis, John J., Ph.D. The Occurrence of a Peripheral T-Cell Lymphoma In A Chronically Immunosuppressed Renal Transplant Patient. *Am J Surg Path* 12:64-70, 1988.
 34. Yeager, A.M., Kaizer, H., Colvin, O.M., Rowley, S.D., Braine, H.G., **Stuart, R.K.**, Saral, R. and Santos, G. Autologous Bone Marrow Transplantation in Acute Nonlymphocytic Leukemia Using Marrow Treated with 4-Hydroperoxycyclophosphamide in Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium. University of Texas M.D. Anderson Hospital and Tumor Institute, Houston, TX, 3:59-68, 1988.
 35. Spivak, J.L., Hogans, B.B., **Stuart, R.K.** Tumor-promoting phorbol esters support the in vitro proliferation of murine pluripotent hematopoietic stem cells. *J Clin Invest* 83(1) 100-107, 1989.
 36. Peters, R.H., Brandon, C.S., Avila, L.A., Colvin, O.M., **Stuart, R.K.** In Vitro Synergism of 4-Hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. *Cancer Chemother. Pharmacol.*, 23: 129-134, 1989.
 37. Carlson LS, **Stuart R**, Osguthorpe JD. Multimodality Treatment of Advanced Head and Neck Carcinoma. *SC Med Assoc J*, 83: 409-411, 1989.
 38. Bunni, M.A., Rembiesa, B.M., Priest, D.G., Sahovic, E., **Stuart, R.** Accumulation of tetrahydrofolates in human plasma after leucovorin administration. *Cancer Chemother. Pharmacol.* 23: 353-357, 1989.
 39. White, D.R., Powell, B.L., Craig, J.B., **Stuart, R.K.**, Schnell, F.M., et. al.: Phase II Trial of High-Dose Cytarabine and Cisplatin in Previously Untreated Non-Small Cell Carcinoma of The Lung: A Piedmont Oncology Association Study. *Cancer.* 65: 1700-3, 1989.
 40. Wingard, J.R., Piantadosi, S., Santos, G.W., Saral, R., Vriesendorp, H.M., Yeager, A.M., Burns, W.H., Ambinder, R.F., Braine, H.G., Elfenbein, G., Jones, R.J., Kaizer, H., May, W.S., Rowley, S.D., Sensenbrenner, L.L., **Stuart, R.K.**, Tutschka, P.J., Vogelsang, G.B., Wagner, J.E., Beschoner, W.E., Brookmeyer, R., Farmer, E.R. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic

- leukemia., J Clin Oncol, 8: 820-30, 1990.
41. Peters, R.H., Brandon, C.S., Avila, L.A., Gale, G.R., and **Stuart, R.K.** Combinations of 4-Hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update. Bone Marrow Purging and Processing in Prog. Biol. Clin. Med., pp. 57-68, 1990.
 42. Peters, R.H. and **Stuart, R.K.** Synergism between 4-Hydroperoxy-Cyclophosphamide and cisplatin: Importance of incubation sequence and measurement of cisplatin accumulation. Biochem. Pharm. 39: 607-609, 1990.
 43. Peters, R.H., Jollow, D.J., and **Stuart, R.K.** Protective role of cellular glutathione against 4-Hydroperoxycyclophosphamide in K-562 cells. Cancer Chemotherapy and Pharmacology, 26: 397-402, 1990.
 44. Marsh, J., Bertino, J., Katz, K., Davis, C., Durivage, H., Rome, L., Richards, F., Capizzi, R., Farber, L., Pasquale, D., **Stuart, R.**, Koletsky, A., Makuch, R. and O'Hollaren, K. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9:371-380, 1991.
 45. Peters, RH, Jollow, DJ, and **Stuart, RK.** Role of glutathione in in vitro interactions between 4-Hydroperoxycyclophosphamide and cisplatin. Cancer Research, 51: 2536-2541, 1991.
 46. Priest, DG, Schmitz, JC, Bunni, MA, and **Stuart, RK.** Pharmacokinetics of Leucovorin Metabolites in Human Plasma as a Function of Dose Administered Orally and Intravenously. J Natl Cancer Inst 83:1806-1812, 1991.
 47. Sahovic EA, Flick J, Graham CD, **Stuart RK.** Isoimmune inhibition of erythropoiesis after ABO-incompatible Bone Marrow Transplantation. Am J Med Sci; 302(6): 369-373, 1991.
 48. Bhalla K, Ross R, Jeter E, Madyastha P, **Stuart RK.** Granulocyte colony stimulating factor improves granulocytopenia in Felty's Syndrome without flare up of arthritis. Am J Hematol 42:230-1, 1993.
 49. **Stuart RK.** Autologous Bone Marrow Transplantation for Leukemia. Seminars in Oncology, Vol 20(5), Suppl 6;October 1993:40-54.
 50. Schmitz JC, **Stuart RK,** Priest DG. Disposition of Folic Acid and its Metabolites; A comparison with Leukovorin. Clin Pharma and Therapeutics, Vol 55;1994:501-508.
 51. Afrin LB, **Stuart RK.** Medical Therapy of Prostate Cancer. J South Carolina Medical Association, Vol 90(5);May 1994:205-258.

52. Hall PD, Benko H, Hogan KR, **Stuart, RK**. The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. *Exper. Hematol.* 23:1256-1260 1995.
53. Afrin LB, Kuppuswamy V, Slater B, **Stuart RK**. Electronic clinical trial protocol distribution via the World-Wide Web: a prototype for reducing costs and errors, improving accrual, and saving trees. *J Amer Med Informatics Assoc.* 4:25-35, 1997.
54. Rogers RL, Javed TA, Ross RE, Virella G, **Stuart RK**, Frei-Lahr D. Transfusion management of an IgA deficient patient with anti-IgA and incidental correction of IgA deficiency after allogeneic bone marrow transplantation. *Amer J Hematol.* 57:326-30, 1998.
55. Ibrahim EM, Al-Mulhim FA, Al-Amri A, Al Muhanna FA, Ezzat AA, **Stuart RK**, Ajarim D. Breast Cancer in the Eastern Province of Saudi Arabia. *Med Oncol* 15, 241-247, 1998.
56. **Stuart RK**. Can breast cancer be prevented? *Ann Saudi Med.* 18:385-388, 1998.
57. Ezzat A, Al Jiffry B, Hildell J, Kfoury H, Rostom A, Sjolint O, Al Sobhi S, **Stuart R**, Ingemansson S. Surgical management of breast cancer in Saudi Arabia: A call for improvement. *Ann Saudi Med.* 18:531-533, 1998.
58. Ezzat A, Raja M, Bakri Y, Subhi J, Memon M, Schwartz P, **Stuart R**. Malignant Ovarian Germ Cell Tumours, A survival and Prognostic Analysis. *Acta Oncologica* 38:455-460, 1999.
59. Ibrahim EM and **Stuart RK**. Evidence-based medicine for the new millennium: critical appraisal and pragmatic approach. *Ann Saudi Med* 19:295-296, 1999.
60. Bhalla KN. Kumar GN. Walle UK. Ibrado AM. Javed T. **Stuart RK**. Reed C. Arbuck SG. Walle T. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatin and 5-fluorouracil in patients with advanced solid tumors. *Clinical Cancer Research.* 5(7):1723-30, 1999.
61. Loynes JT, Kallab A, **Stuart RK**. Neutrophil eccrine hydradenitis: a case report and review of the literature. *Hospital Physician* 35:70-73, 1999.
62. Ibrahim EM, Ezzat AA, Raja MA, Rahal MM, Ajarim DS, Mann B, Baloush A, **Stuart RK**, Bazarbashi SN. Primary gastric non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. *Ann Oncol* 10:1441-1449, 1999.
63. Ezzat AA, Ibrahim EM, **Stuart RK**, Ajarim D, Bazarbashi S, El-Foudeh MO, Rahal M, Al-Sayed A, Berry J. Adding high-dose tamoxifen to CHOP does not influence

- response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. *Med Oncol* 17:39-46, 2000.
64. Ezzat A, Ibrahim E, Ajarim D, Rahal M, Raja M, **Stuart R**, Tulbah A, Al-Malik O, Bazarbashi S. High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. *Breast Cancer Research and Treatment* 1755:1-8, 2000.
 65. Ezzat A, Ibrahim E, Raja M, Al-Sobhi S, Rostom A, **Stuart RK**. Locally advanced cancer of the breast: high proportion of stage III disease in a young population. *Med Oncol* 17: 39-46, 2000.
 66. Harris JE, Ryan L, Hoover HC, **Stuart RK**, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283. *Journal of Clinical Oncology* 2000; 18(1):148-157.
 67. Gyger M, **Stuart RK**, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. *Bone Marrow Transplantation*. 26(1):1-16, 2000
 68. Ezzat AA, Ibrahim EM, El Weshi AN, Khafaga YM, AlJurf M, Martin JM, Ajarim DS, Bazarbashi SN, **Stuart RK**, Zucca E. Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. *Head & Neck*. 23(7):547-58, 2001.
 69. Frankel AE. Baer MR. Hogge DE. **Stuart RK**. Immunotherapy of acute myeloid leukemia. *Current Pharmaceutical Biotechnology*. 2(3):209-15, 2001
 70. Nounou R, Al-Zahrani H H, Ajarim DS, Martin J, Iqbal A, Naufal R, **Stuart R**, Roberts G, Gyger M. Extramedullary myeloid cell tumours localised to the mediastinum: a rare clinicopathological entity with unique karyotypic features. *Journal of Clinical Pathology*. 55(3):221-5, 2002
 71. Harris JE, Ryan L, Hoover HC, **Stuart RK**, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283. *Classic Papers and Current Comments. Highlights of Gastrointestinal Cancer Research*. 6: 849-859, 2002
 72. Day TA, Davis BK, Gillespie, MB, Joe JK, Kibbey M, Martin-Harris M, Neville B, Richardson MS, Rosenzweig S, Sharma A, Smith MM, Stewart S, **Stuart RK**. Oral cancer treatment. *Current Treatment Options in Oncology*. 4: 27-41, 2003.
 73. Onitilo AA, Lazarchick L, Brunson CY, Frei-Lahr D, **Stuart RK**. Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. *Transplant Proc*. 35:3089-92, 2003.

74. Day TA, Deveikis J, Gillespie MB, Joe JK, Ogretmen B, Osguthorpe JD, Reed SG, Richardson MS, Rossi M, Saini R, Sharma AK, **Stuart RK**. Salivary gland neoplasms. Current Treatment Options in Oncology. 5:11-26, 2004.
75. Bilic M, Quigley DI, **Stuart RK**, Wolff DJ. Jumping translocation of 1q in BCR/ABL-positive acute lymphoblastic leukemia. Cancer Genet Cytogenet. 172:90-1, 2007.
76. Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, **Stuart RK**, Spicer EK, and Fernandes DJ. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of *bcl-2* mRNA. Blood 109:3069-3075, 2007.
77. Koch D, Christiansen L, Lazarchick J, **Stuart R**, Wilner I, Rueben A. Posttransplant lymphoproliferative disorder (PTLD): the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transplantation, 13:904-912, 2007.
78. Amria S, Cameron C, **Stuart R**, Haque A. Defects in HLA-class II antigen presentation in B-cell lymphomas. Leukemia & Lymphoma, 49: 353-355, 2008.
79. Watkins JM, **Stuart RK**, Davis BK, Day TA, Chaudhary UB, Sharma AK. Long-term survival following salvage reirradiation with concurrent chemotherapy for recurrent head and neck cancer. J South Carol Med Assoc. 104: 36-39, 2008.
80. Znoyko I, **Stuart RK**, Ellingham T, Winters J, Wolff DJ, and Quigley DI. Tetraploidy and 5q deletion in MDS: a case report. Cancer Genet Cytogenet. 2008 May;183(1):64-8.
81. Vu KN, Day TA, Gillespie MB, Martin-Harris B, Sinha D, **Stuart RK**, Sharma AK. Proximal esophageal stenosis in head and neck cancer patients after total laryngectomy and radiation. ORL J Otorhinolaryngol Relat Spec. 2008;70(4):229-35. Epub 2008 May 9.

ABSTRACTS:

1. **Stuart, R. K.** Humoral Suppression of Host Hematopoietic Stem Cells During Graft-Versus-Host Reactions. *Exp. Hematol.* 1: 288, 1973.
2. Sensenbrenner, L. L. and **Stuart, R. K.** Effect of Drugs on the Growth of CFU-s in Diffusion Chambers in Mice. *Exp. Hematol.* 2: 321, 1974.
3. **Stuart, R. K.** and Sensenbrenner, L. L. Specific Inhibition of Tumors by Humoral Factors in Immune Mice. *Proc. Am. Assoc. Cancer Res.* 15: 130, 1974.
4. Burke, P. J., Karp, J. E., **Stuart, R. K.** and Ownes, A. H., Jr. Comparison of Regulators of Cellular Proliferation in Mouse, Rat and Man. *Exp. Hematol.* 2: 284, 1974.
5. **Stuart, R. K.** and Sensenbrenner, L. L. Adverse Effects of Short-Term Food Deprivation on Transplanted Hematopoietic Cells. *Exp. Hematol.* 5 (Suppl. 2): 44, 1977.
6. Sharkis, S. J., Sensenbrenner, L. L., Ahmed, A., **Stuart, R. K.**, Wiktor-Jedrzejczak, W. and Sell, K. W. The Effect of High Specific Activity Tritiated Thymidine on CFUs from Anti-Theta Serum Sensitive Regulatory Cell (TSRC) Depleted Bone Marrow Transplanted into W/W^v Anemic Mice. *Exp. Hematol.* 6 (Suppl. 3): 18, 1978.
7. **Stuart, R. K.** and Sensenbrenner, L. L. Influence of Nutrition on Hematopoietic Recovery. *Proc. Am. Assoc. Cancer Res.*, 19: 81, 1978.
8. Sharkis, S. J., Spivak, J., **Stuart, R. K.**, Misiti, J., Sensenbrenner, L. L., Wiktor-Jedrzejczak, W. and Ahmed, A. Thymic Control of Hematopoiesis: Effect of Anti-Theta Serum + Complement on Proliferating Precursors (CFU-c and CFU-e) in Normal and Anemic W/W^v Mice. *Blood* 52 (Suppl. 1): 215, 1978.
9. Spivak, J., Misiti, J., **Stuart, R. K.**, Sharkis, S. J. and Sensenbrenner, L. L. Selective Suppression and Potentiation of Hematopoietic Precursor Cell Proliferation by Oubain. *Blood* 52 (Suppl. 1): 215, 1978.
10. **Stuart, R. K.**, Braine, H. G., Saral, R., Lietman, P. S. and Fuller, D. J. Carbenicillin-Trimethoprim/Sulfamethoxazole Versus Carbenicillin-Gentamicin as Empiric Therapy of Infection in Granulocytopenic Patients: A Prospective, Randomized, Double-Blind Study. *Proc. Am. Soc. Clin. Oncol.*, 20: 417, 1979.
11. Sensenbrenner, L. L. and **Stuart, R. K.** High Dose Cyclophosphamide in the Treatment of Aplastic Anemia. *Exp. Hematol.*, 7 (Suppl. 6):11, 1979.
12. **Stuart, R. K.** and Hamilton, J. Tumor Promoting Phorbol Esters Stimulate Hematopoietic Colony Formation In Vitro. *Blood* 54 (Suppl. 1): 176, 1979.

13. Pelus, L. M. Broxmeyer, H. E., **Stuart, R. K.**, Kurland, J. I. and Moore, M. A. S. Specific Regulation of Macrophage Proliferation by Prostaglandin E. *Exp. Hematol.* 7 (Suppl. 6): 113, 1979.
14. Szeluga, D. J., **Stuart, R. K.** and Santos, G. W. Nutritional Support of Bone Marrow Transplant Recipients. *Clin. Res.* 28: 232A, 1980.
15. Wingard, J. R., **Stuart, R. K.**, Saral, R. and Burns, W. H. Anti-Cytomegalovirus Activity of Trifluorothymidine and Acycloguanosine. *Herpes Virus Conf.*, Atlanta, Georgia, March, 1980.
16. **Stuart, R. K.** and Pollack, M. Pseudomonas Aeruginosa Exotoxin A Inhibits Proliferation of Human Bone Marrow Progenitor Cells. *Am. Fed. Clin. Res.*, 1980.
17. Sensenbrenner, L. L., Sharkis, S. J., Spivak, J., Sieber, F. and **Stuart, R. K.** Isolation of Erythroid Progenitor Cells from Bone Marrow Using Fluoresceinated Wheat Germ Agglutinin. *Exp. Hematol.* 8 (Suppl. 7): 128, 1980.
18. **Stuart, R. K.** and Sharkis, S. J. Erythroid Repopulating Ability of Cells from Long-Term Bone Marrow Cultures (LTMC). 2nd Conf. Hemoglobin Switching, Airlie House, Virginia, June 22-26, 1980.
19. **Stuart, R. K.**, Shadduck, R. K. and Hamilton, J. A. Tumor-Promoting Phorbol Esters Stimulated Myeloid Colony Formation Without Colony Stimulating Factor. *Exp. Hematol.* 8 (Suppl. 7): 103, 1980.
20. Sharkis, S. J., Sensenbrenner, L. L., Spivak, J., Sieber, F. and **Stuart, R. K.** Isolation of Erythroid Progenitor Cells from Bone Marrow Using Fluoresceinated Wheat Germ Agglutinin. 2nd Conf. Hemoglobin Switching, Airlie House, Virginia, June 22-26, 1980.
21. Sieber, F., **Stuart, R. K.** and Spivak, J. L. Dual Effect of Tumor-promoting Phorbol Esters on Mouse Hematopoietic Progenitor Cells. *J. Cell Biol.* 87: 18a, 1980.
22. **Stuart, R. K.**, Sensenbrenner, L. L., Waheed, A., Camaratti, C. and Shadduck, R. K. Tumor Promoting Phorbol Esters Inhibit Binding of colony Stimulating Factor to Bone Marrow Cells. *Exp. Hematol.* 9 (Suppl. 9): 133, 1981.
23. Kaizer, H., **Stuart, R. K.**, Colvin, M., Korbling, M., Wharam, M. D. and Santos, G. W. Autologous Bone Marrow Transplantation in Acute Leukemia: A Pilot Study Utilizing In Vitro Incubation of Autologous Marrow with 4-Hydroperoxycyclophosphamide (4 HC) Prior to Cryopreservation. *Proc. Am. Soc. Clin. Oncol.* 22: 483, 1981.

24. Sieber, F., Meagher, R. C., **Stuart, R. K.**, Sensenbrenner, L. L., Sharkis, S. J. and Spivak, J. L. Susceptibility to Merocyanine 540- Mediated Photolysis as a Differentiation Marker in Murine and Human Hematopoietic Stem Cells. *Exp. Hematol.* 9 (Suppl. 9): 149, 1981.
25. Santos, G. W., Bias, W., Burns, W., Eifenbein, G., Kaizer, H., Saral, R., Sensenbrenner, L. L., **Stuart, R. K.** and Tutschka, P. Syngeneic Bone Marrow Transplantation, Baltimore Experience. *Exp. Hematol.* 9 (Suppl. 9): 141, 1981.
26. Kaizer, H. **Stuart, R. K.**, Colvin, M., Korbling, M., Wharam, M. and Santos, G. W. Autologous Bone Marrow Transplantation in Acute Leukemia: A Pilot Study Utilizing In Vitro Incubation of Autologous Marrow with 4-Hydroperoxycyclophosphamide (4 HC) Prior to Cryopreservation. *Exp. Hemat.* 9 (Suppl. 9): 190, 1981.
27. Sieber, F., **Stuart, R. K.**, Sensenbrenner, L. L. and Sharkis, S. J. Susceptibility to Merocyanine 540-Mediated Photolysis as a Differentiation Marker in Human Hematopoiesis Stem Cells. *Blood* 58 (Suppl. 1): 102a, 1981.
28. Eifenbein, G. J., Mellits, e. D., Bias, W. B., Braine, H. G., Burns, W. H., Kaizer, H., Saral, R., Sensenbrenner, L. L., **Stuart, R. K.**, Tutschka, P. J. and Santos, G. W. Bone Marrow Transplantation (BMT) for Severe Aplastic Anemia (AA): 75 Consecutive Cases. *Blood* 58 (Suppl. 1): 172a, 1981.
29. Santos, G. W., Tutschka, P. J., Beschorner, W. E., Burns, W. H., Bias, W. B., Eifenbein, G. J., Kaizer, H., Saral, R., Sensenbrenner, L. L. and **Stuart, R. K.** Marrow Transplantation in Acute Non-Lymphocytic Leukemia (ANL) Following Busulfan (BU) and Cyclophosphamide (CY). *Blood* 58 (Suppl. 1): 176a, 1981.
30. Kaizer, H., Cote, J. P., Sharkis, S. J., **Stuart, R. K.** and Santos, G. W. Autologous Bone Marrow Transplantation in Acute Leukemia: The Use of In Vitro Incubation of Tumor-Marrow Mixtures with 4-Hydroperoxycyclophosphamide (4HC) In a Wister-Furth Rad Model of Acute Myelogenous Leukemia (WF-AML). *Proc. Amer. Assoc. Cancer Res.* 23: 194, 1982.
31. Strauss, L. C., **Stuart, R. K.** and Civin, C. I. Antigenic Analysis of Hematopoiesis. *Proc. Amer. Assoc. Cancer Res.* 23: 266, 1982.
32. Kaizer, H., **Stuart, R. K.**, Fuller, D. J., Braine, H. G., Saral, R., Colvin, M., Wharam, M. D. and Santos, G. W. Autologous Bone Marrow in Acute Leukemia: Progress Report on a Phase I Study of 4-Hydroperoxycyclophosphamide (4HC) Incubation of Marrow Prior to Cryopreservation. *Proc. Amer. Soc. Clin. Oncol.* 1: 1982.
33. **Stuart, R. K.** and Sharkis, S. J. Erythroid Repopulating Ability of Cells from Long-Term Bone Marrow Cultures (LTMC). *Exp. Hematol.* 10 (Suppl. 11): 70, 1982.

34. Sieber, F., **Stuart, R. K.**, Sensenbrenner, L. L., Sharkis, S. J. and Spivak, J. L. Plasma Membrane Properties of Normal Human Hematopoietic Progenitor Cells and Leukemia Cells. *Exp. Hematol.* 10 (Suppl. 11): 85, 1982.
35. Strauss, L., Civin, C., **Stuart, R. K.**, Skubitz, K., August, J. T. and Sensenbrenner, L. L. Antigenic Analysis of Granulopoiesis. *Exp. Hematol.* 10 (Suppl. 11): 129, 1982.
36. **Stuart, R. K.**, Sensenbrenner, L. L. and Santos, G. W. Severe Aplastic Anemia: Comparison of Bone Marrow Transplantation (BMT) with Antilymphocyte Globulin (ALG). *Blood* 60 (Suppl. 1): 173a, 1982.
37. Bishop, C., Gordon, A., Townsend, R., **Stuart, R. K.** and Saral, R. comparison of Double Lumen and Single Lumen Hickman Catheters in Oncology Patients. Association for Practitioners in Infection Control, 1983.
38. Szeluga, D. J., **Stuart, R. K.** and Santos, G. W. Nutritional Assessment by Isotope Dilution Analysis of Body Composition. *Gastroenterology* 84: 1411, 1983.
39. Rowley, S. D. and **Stuart, R. K.** 4-Hydroperoxycyclophosphamide (4HC) Effects on Human Pluripotent Stem Cells (CFU-GEMM) *In Vitro*. *Exp. Hematol.* 11 (Suppl. 14): 8, 1983.
40. **Stuart, R. K.** and Luk, G. D. Polyamine Biosynthesis: Role in Murine Hematopoietic Cell Proliferation and Differentiation. *Exp. Hematol.* 11 (Suppl. 14): 54, 1983.
41. Santos, G. W., Bias, W. B., Beschorner, W. E., Burns, W. H., Elfenbein, G. J., Kaizer, H., Saral, R., Sensenbrenner, L. L., **Stuart, R. K.**, Tutschka, P. J. and Yeager, A. M. Allogeneic and syngeneic marrow Transplantation for Acute Lymphocytic Leukemia (ALL) in Remission - Baltimore Experience. *Exp. Hematol.* 11 (Suppl. 14): 132, 1983.
42. May, W. S., Jr., **Stuart, R. K.**, Sensenbrenner, L. L., Jacobs, S. and Cuatrecasas, P. Regulation of Surface Transferrin Receptors on HL-60 Cells Incubated with Phorbol Dibutyrate (PDBU). *Exp. Hematol.* 11 (Suppl. 14): 200, 1983.
43. Kaizer, H., **Stuart, R. K.**, Brookmeyer, R., Colvin, M. and Santos, G. W. Autologous Bone Marrow Transplantation (BMT) in Acute Leukemia: A Phase I Study of *In Vitro* Treatment of Marrow with 4-Hydroperoxycyclophosphamide (4HC) to Purge Tumor Cells. *Blood* 62 (Suppl. 1): 224, 1983.
44. Rowley, S., **Stuart, R. K.** and Colvin, M. 4-Hydroperoxycyclophosphamide (4HC) Effects on Human Long Term Marrow Culture (LTMC). *Blood* 62 (Suppl. 1):229, 1983.
45. **Stuart, R. K.** and Mangan, K. F. Apparent Cure of 5q- Refractory Anemia by Syngeneic Bone Marrow Transplantation. *Blood* 62 (Suppl. 1): 230, 1983.

46. Rowley, S. D. and **Stuart, R. K.** Methylprednisolone (MP) Enhanced Progenitor Cell Expression. *Exp. Hemat.* 12 (Suppl. 6): 27, 1984.
47. **Stuart, R. K.**, Braine, H. G., Yeager, A., Rowley, S., Kaizer, H., Colvin, M. and Santos, G. W. Autologous Bone Marrow Transplantation (BMT) in Acute Leukemia: A Phase II Study of 4- Hydroperoxycyclophosphamide (4HC) Marrow Purging. *Exp. Hematol.* 12 (Suppl. 6): 264, 1984.
48. **Stuart, R. K.** and Sensenbrenner, L. L. Severe Aplastic Anemia (SAA): Comparison of Bone Marrow Transplantation (BMT) with Immunosuppressive Therapy. *Blood* 64 (Suppl. 1): 345, 1984.
49. Strauss, L. C., Rowley, S. D., Loken, M. R., **Stuart, R. K.** and Civin, C. I. Primitive Normal Lymphohematopoietic Progenitor Cells Express the MY-10 Antigen: Further Characterization. *Blood* 64 (Suppl. 1): 380, 1984.
50. Spivak, J. L., **Stuart, R. K.** and Hogans, B. A Tumor Promoting Phorbol Ester Enhances the In Vitro Survival of Pluripotent Hematopoietic Stem Cells. *Blood* 66 (Suppl. 1): 537, 1985.
51. Sensenbrenner, L. L., **Stuart, R. K.**, Santos, G. W. and Saral, R. Improved Marrow Transplantation (BMT) for Severe Aplastic Anemia (SAA) Utilizing Cyclophosphamide (CY) and Cyclosporine (CSA) Pretreatment. *Blood* 66 (Suppl. 1.): 902, 1985.
52. **Stuart, R. K.**, Sensenbrenner, L. L., Zinkham, W. H., Santos, G. W. and Saral, R. Successful Elective Bone Marrow Transplantation (BMT) in an Untransfused Patient with Fanconi's Anemia. *Blood* 66 (Suppl. 1): 905, 1985.
53. Rowley, S., **Stuart, R. K.**, Hess, A., Donnenberg, A., Saral, R. and Santos, G. Prevention of Acute Graft versus Host Disease (GVHD) by Methylprednisolone (MP) Incubation of Donor Bone Marrow. *Blood* 66 (Suppl. 1): 930, 1985.
54. Young N and Principal Investigators. Multicenter Trial of Antithymocyte Globulin (ATG; Upjohn) in Acute, Chronic and Moderate Aplastic Anemia and Other Bone Marrow Failure States. *Blood* 10:145a, 1987.
55. Peters, RH and **Stuart, RK.** Synergistic effect of 4-Hydroperoxy-Cyclophosphamide (4-HC) and cisplatin (CP) for ex-vivo bone marrow purging. *Proc. Am. Assoc. Canc. Res.* 28: 1644, 1987.
56. Peters, RH and **Stuart, RK.** Cisplatin: potential candidate for combination with 4-Hydroperoxycyclophosphamide in ex vivo bone marrow purging. *Exp. Hematol.* 15: 253, 1987.
57. Peters, RH, Gale, GR, and **Stuart, RK.** Ex vivo treatment of L1210 cells and normal murine marrow cells with 4-Hydroperoxycyclophosphamide (4-HC) and cisplatin.

Blood 72: 400a, 1988.

58. Peters, RH and **Stuart, RK**. Differential combination effect of cisplatin and 4-hydroperoxycyclophosphamide in human committed hematopoietic progenitor cells. Proc. Am. Assoc. Canc. Res. 29: 479, 1988.
59. Peters, RH and **Stuart, RK**. Combinations of 4-Hydroperoxycyclophosphamide (4-HC) and cisplatin for autologous marrow transplantation: an update. 2nd International Symposium on Bone Marrow Purging and Processing, 1989.
60. Peters, RH, Jollow, DJ, and **Stuart, RK**. Synergism between 4-Hydroperoxycyclophosphamide (4-HC) and cisplatin (CP): role of glutathione. Proc. Am. Assoc. Canc. Res. 30: 544, 1989.
61. Schiff, RD, Thompson, KA, and **Stuart, RK**. Low-Dose Cytarabine (LDC) and 13-cis-Retinoic Acid (RA) in the treatment of Myelodysplastic Syndromes (MDS) and Poor-Prognosis Acute Myeloid Leukemia (PP-AML). Blood 76 (Suppl 1): 317a, 1990.
62. Madyastha, PR, Jeter, EK, **Stuart, RK**, and Cate, JC. Non-detectability of neutrophil antigens (NB1, 9A) after marrow transplantation: evidence of marrow engraftment. 46th Annual Meeting of the American Association of Blood Banks, 1993.
63. Powell, BL, Cruz, JM, Lyerly, ES, Russell, GB, Wood, JH, **Stuart, RK**, Chorley, HM, Capizzi, RL. Sequential High Dose ARA-C and Asparaginase in Untreated AML: Efficacy of a Single Daily Dose of High Dose ARA-C. Blood 82 (Suppl 1): 502, 1993.
64. Hall, P, Benko, H, Hogan, K, **Stuart, RK**. The Influence of Serum Tumor Necrosis Factor- α (TNF) & Interleukin-6 (IL6) Levels on Non-Hematologic Toxicity (NHTOX) & Hematologic Recovery In Patients (PTS) with Acute Myelogenous Leukemia (AML). Blood 82 (Suppl 1): 502, 1993.
65. Hall, P, Frei-Lahr, D, Goulet, J, Sahovic, E, **Stuart, R**. The Combination of Pentoxifylline (P) & Ciprofloxacin (C) does not decrease the toxicity of Bone Marrow Transplantation (BMT). Blood 84 (Suppl 1): 492, 1994.
66. Javed, T, Reed, C, Walle, T, **Stuart, R.K**, Ibrado, A.M, Bhalla, K. A Regimen of Paclitaxel (P), Cisplatin (CP) and 5-Fluorouracil (FU) followed by G-CSF is highly active against Epidermoid and Adenocarcinoma of Esophagus. Am. Soc. Clin. Oncol. 14 456, 1995.
67. Feldman, E, Geller, RB, Seiter, K, Heffner, L, **Stuart, R**, Bhalla, K. Pixy-321 in combination with high dose Cytarabine and Mitoxantrone in poor prognosis acute Myeloid Leukemia (AML). Blood 86 (Suppl 1): 520, 1995.
68. Hall, P,D, Sele, S, Kneuperhall, R, & **Stuart, R.K**. The interaction of maintenance Interferon (IFN) with Cytolytic Cells in Multiple Myeloma (MM) Patients after Cytotoxic Chemotherapy. Blood 86 (Suppl 1): 834, 1995.

69. Beveridge R, Schuster M, Waller E, **Stuart R**, Abboud C, Cruickshank S, Menchaca D, Macri M, Connaghan DG. Randomized, double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients (Pts) following autologous bone marrow transplantation (ABMT). *Blood* 90(Suppl 1):580a, 1997.
70. Ezzat A, Ranginwala M, Berry J, Bazarbashi S, **Stuart R**, Rahal M, Raja M, Bartholomew L. Phase II study of ifosfamide and cisplatin (I/P) in metastatic breast cancer (MBC). Proceedings of the 21st Annual San Antonio Breast Cancer Symposium, Dec 1998.
71. Rahal M, Ezzat A, Berry J, Raja MA, Bazarbashi S, **Stuart RK**. Chronic Administration of Etoposide (VP16) Followed by CNOP (Cyclophosphamide, Novantrone, Oncovin, and Prednisone) in Elderly Patients (PTS) with Aggressive Non-Hodgkin's Lymphoma. *Proc. Am. Soc. Clin. Oncol.* 18:34a, 1999.
72. **Stuart R**, Ezzat A, Ibrahim E, Ranginwala M, Ajarim D, El-Foudeh M, Raja M, Bazarbashi S, Rahal M. CHOP vs CHOP + High-Dose Tamoxifen in the Management of Aggressive Non-Hodgkin's Lymphoma: Interim analysis of a Prospective, Randomized Trial. *Proc. Am. Soc. Clin. Oncol.* 18:38a, 1999.
73. Ibrahim EM, Ezzat AA, **Stuart RK**, Ajarim DS, Raja M. Stage III Breast Cancer: Single Institution Experience. *Proc. Am. Soc. Clin. Oncol.* 18:96a, 1999.
74. Harris J, Ryan L, Hoover H, **Stuart R**, Oken M, Benson A, Mansour E, Haller D, Manola J, Hanna M. Delayed Cutaneous Hypersensitivity (DCH) as a Measure of Effectiveness for Adjuvant Active Specific Immunotherapy (ASI) in Surgically Resected Stage II and III Colon Cancer. *Proc. Am. Soc. Clin. Oncol.* 18:438a, 1999.
75. Raja M, Ezzat A, Ibrahim E, Bazarbashi S, Rahal M, **Stuart RK**. Prospective Comparative Study of 5HT-3 Antagonists in Moderately Emetogenic Chemotherapy. *Proc. Am. Soc. Clin. Oncol.* 18:604a, 1999.
76. Seth P, Al-Nasser A, Aslam M, Ayoub O, **Stuart R**, Qadi A, Al Saeed H, Al Sharif F, Al Mohareb F, Gyger M. Impact of Pre-Transplant Hepatitis Virus Infection on Allogeneic Bone Marrow Transplantation Outcome. *Blood* 94(Suppl 1):342a, 1999.
77. Sahovic E, Al Suliman A, Aslam M, Seth P, Akhtar J, Aljurf M, Chaudhri N, Sullivan A, Al-Quraishi F, Colcol E, Magpantay C, Gyger M, **Stuart R**. Successful Prevention of CMV Disease After Allogeneic BMT in 100 Consecutive CMV Seropositive Recipients. *Blood* 94(Suppl 1):372b, 1999.
78. Ibrahim EM, Ezzat AA, Raja MM, Ajarim DS, Mann B, Baloush A, **Stuart RK**, Bazarbashi SN. Primary Large B-Cell (LBCL) Non-Hodgkin's Lymphoma: Analysis of 185 Patients. *Proc. Am. Soc. Clin. Oncol.* 19:34a, 2000.

79. Seth P, **Stuart R**, Sahovic E, Chaudhary MA, Aljurf M, Colcol E, Aslam M, Chaudhri N, Mohareb F, Gyger M. Risk factors and clinical characteristics of hepatitis B virus (HBV) reactivation post allogeneic stem cell transplantation (ASCT) in patients previously infected and immune to HBV. *Biol Blood Marrow Transpl* 7: 88, 2001.
80. Bazarbashi S, Raja M, Rahal M, El Weshi A, Pai C, El Foudeh M, Kerr I, Memon M, Ajarim D, Ezzat A, **Stuart R**.. High Response Rate to Combination Cisplatin, 5-Fluorouracil and Interferon Alpha in the Treatment of Advanced Esophageal Carcinoma: a Confirmatory Phase II Trial. *Proc. Am. Soc. Clin. Oncol.* 20: 160a, 2001
81. El Weshi A, Ajarim D, Bazarbashi S, Raja M, Rahal M, El Foudeh M, El Husseiny G, Memon M, **Stuart R**, Ezzat A. T-Cell-Rich B-Cell Lymphoma (TCRBCL): Presentation and Treatment Outcome. Single Center Experience with 29 Patients. *Proc. Am. Soc. Clin. Oncol.* 20: 297a, 2001
82. Vu K, Day TA, Gillespie MB, **Stuart RK**, Sharma AK. Proximal Esophageal Strictures in Head and Neck Cancer Patients Following Laryngectomy and Radiotherapy. American Radium Society, 86th Annual Meeting, 2004.
83. M. Boyd Gillespie, Martin B. Brodsky, Terry A. Day, Anand K. Sharma, **Robert K. Stuart**, Bonnie Martin-Harris. Dysphagia after Treatment of Advanced Head and Neck Cancer. Sixth International Conference on Head and Neck Cancer, Washington DC, 2004.
84. Sharma A, Vu K, Meyer M, Day T, Gillespie M, Koybasi S, **Stuart R**. Weekly Paclitaxel and Cisplatin Concurrent with Conformal Radiotherapy in Locally Advanced Head and Neck Cancer. American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting, September 22, 2004
85. Das A, Karmakar S, **Stuart RK**, Patel SJ, Banik NL, Ray SK. Plant derived flavonoids induced proteolytic activities of calpain and caspase-3 for apoptosis in human malignant glioblastoma U87MG cells. *Proc Amer Assoc Cancer Res*, 2005
86. Levis M, Smith BD, Beran M, Baer M, Erba HP, Cripe L, Coutre S, Advani A, Perl A, Devetten M, **Stuart R**, Tallman M, Brown P, Tremmel L, Small D. A randomized open-label study of lestaurinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. *Blood* 106: 121a, 2005.
87. Grant S, Sullivan D, Roodman, D, **Stuart R**, Perkins EB, Ramakrishnan V, Wright J, Colevas AD, Roberts JD. Phase I trial of bortezomib (NSC 681239) and flavopiridol (NSC 649890) in patients with recurrent or refractory B-cell neoplasms. *Blood* 106: 933a, 2005.

88. Soundararajan,S, Otake,Y, Spicer,E, Smith, J, **Stuart, RK**, Fernandes, DJ. Stabilization of bcl-2 mRNA in CLL cells by nucleolin. Abstr. Proc. Am. Assoc. Cancer Res., 4: 958, 2006
89. Sawhney R, Dragun A, **Stuart RK**, Chaudhary UB, Day T, Gillespie MB, Sharma A. Concurrent split course hyperfractionated radiotherapy (Hfx RT) with biweekly cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): The MUSC experience. Proc. Am. Soc. Clin. Oncol. 24: 5578a, 2006.
90. Giles FJ, Stock W, Vey N, Seiter K, DeAngelo DJ, Boskovic D, **Stuart RK**, Johnson B., Cahill AL, O'Brien S. A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without Cloretazine® in patients with first relapse of acute myeloid leukemia (AML). Blood; 108: 1970a, 2006.
91. Chau M, Otake Y, **Stuart RK**, Fernandes DJ, Ajami AM. Imidazoacridinones are bifunctional targeting agents active in leukemia cells. Blood; 108: 2323a, 2006.
92. Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz J E, Thakuri M, Carter T, **Stuart R K**, Larson RA. A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7012
93. Schiller GJ, DeAngelo DJ, Pigneux A, Vey N, Kell J, Solomon SR, **Stuart RK**, Johnson BL, O'Brien S, Giles FJ. Phase II study of VPN404101M (Cloretazine®) in elderly patients with do novo poor risk acute myelogenous leukemia (AML). Blood; 109: 279a, 2007.
94. Chen W, Sridharan V, Soundararajan S, Otake Y, **Stuart R**, Jones D, Fernandes D. Activity and mechanism of action of AS1411 in acute myeloid leukemia cells. Blood; 109: 479a, 2007.
95. Watkins JM, Herrin AE, Shirai KS, Garrett-Mayer E, **Stuart RK**, Gillespie MB, Day TA, Sharma AK. Low-dose weekly platinum-based chemotherapy with concurrent radiotherapy (CRT) for locally advanced head/neck cancer (LAHNC). [Abstract accepted for oral presentation to the 7th International Conference on Head and Neck Cancer, San Francisco, California: 19 Jul 2008.
96. Susan O'Brien, Gary Schiller, **Robert Kenneth Stuart**, Diana Hudak, and Francis Giles
Survival after Complete Response to Treatment with Laromustine (CLORETAZINE®) in Elderly Patients with *De Novo* Poor Risk Acute Myelogenous Leukemia (AML). Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 940.

97. **Robert Kenneth Stuart**, Gary Acton AS1411-201 Investigator Group. Relapsed and Refractory Acute Myeloid Leukemia (AML) Treated with AS1411 and Cytarabine: A Randomized Phase II Trial. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1935.
98. Jeffrey E. Lancet, Elliott F. Winton, **Robert K. Stuart**, Michelle Burton, Christopher Cubitt, Michelle Blaskovich, John Wright, Said Sebti, and Daniel Sullivan. A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1945.
99. Michael Maris, Larry D. Cripe, **Robert K Stuart**, Farhad Ravandi, Glenn C Michelson, Rachel E. Hawtin, Lyra E Ericson, and Craig J. Berman. Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study). Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1951.
100. Steven Grant, Daniel Sullivan, David Roodman, **Robert K Stuart**, Edward Perkins, Sarah Kolla, Viswanathan Ramakrishnan, John Wright, Alexander Dimitri Colevas, M B Tombes, and John D Roberts. Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1573.

BOOK CHAPTERS:

1. **Stuart, R. K.** Nutritional Support. In Management of the Cancer Patient: A Guide for the Practicing Physician (Abeloff, M. D., Ed.). The Johns Hopkins University Press, Baltimore, Maryland, pp. 17-57, 1979.
2. Margolis, S. and **Stuart, R. K.** Nutritional Disorders. In Principles and Practice of Medicine (Harvey, A. M., Johns, R. J., McKusick, v. A., Owens, A. H., Jr. and Ross, R. S., Eds.) Appleton Century Crofts, New York, N. Y., 1984.
3. Yeager, A. M., Kaizer, H., Braine, H. G., Colvin, M., Rowley, S. D., Saral, R., Fuller, D. J., Ambinder, R. F., Burns, W. H., May, S., Sensenbrenner, L., **Stuart, R. K.**, Vogelsang, G. B., Wingard, J. R. and Santos, G. W. In Minimal Residual Disease in Acute Leukemia. Martinus Nijhoff, Boston, 1986.
4. Graham, C.D. and **Stuart, R.K.** Pain Management of Cancer Patients. In Urology Annual (Rous S.N., Ed.) Appleton & Lange, Division of Prentice Hall, Englewood Cliffs, New Jersey, 1990.

5. **Stuart, R.K.** The Role of Systemic Cytotoxic Chemotherapy in the Management of Muscle-Invasive Bladder Cancer. In Urology Annual (Rous S.N., Ed.). W. W. Norton & Company, Inc., New York, N.Y., pp. 117-137, 1993.
6. **Stuart R.K.** Chronic Lymphocytic Leukemia. In Problem Solving in Hematology; (Gross, Ed.), Williams & Wilkins, Media, PA 1997.

Revised: 01/2009